First-line alectinib for ALK-positive lung cancer: is there room for further improvement?

Article Page

Abstract

In the present editorial we describe the therapeutic achievements in the treatment of patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). We focus on the major breakthroughs we have been witnessing in this context, from the introduction of crizotinib as the first approved targeted drug, to the meaningful improvement in terms of clinical benefit that alectinib, a second generation ALK-inhibitor, has recently provided over crizotinib. Finally, we address major trends of clinical research in this setting, and whether this might translate into further clinical improvement in the near future.

Keywords: alectinib, ALK, brain metastases, brigatinib, ceritinib, crizotinib, non-small cell lung cancer.

Citation: Addeo A, Metro G. First-line alectinib for ALK-positive lung cancer: is there room for further improvement? Drugs in Context 2018; 7: 212537. DOI: 10.7573/dic.212537

Contributions: Giulio Metro wrote the first draft of the editorial and both authors reviewed it for important intellectual content.

Disclosure and potential conflicts of interest: The authors declare that there is no conflict of interest regarding the publication. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors are available for download at https://www.drugsincontext.com/wp-content/uploads/2018/06/dic.212537-COI.pdf

Funding declaration: There was no funding for this manuscript.

Copyright: Copyright © 2018 Addeo A, Metro G. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2018 Addeo A, Metro G. https://doi.org/10.7573/dic.212537. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://www.drugsincontext.com/first-line-alectinib-for-alk-positive-lung-cancer-is-there-room-for-further-improvement

Correspondence: Giulio Metro, MD, Staff Physician, Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, via Dottori, 1, 06156, Perugia, Italy. giulio.metro@yahoo.com

Provenance: invited; externally peer reviewed.

Submitted: 10 May 2018; Peer review comments to author: 6 June 2018; Revised manuscript received: 9 June 2018; Accepted: 11 June 2018; Publication date: 10 July 2018.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252772009.

For all manuscript and submissions enquiries, contact the Editorial office dic.editorial@bioexcelpublishing.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

Download free full text PDF